Risk factors for breakthrough varicella in healthy children
Open Access
- 1 December 1998
- journal article
- clinical trial
- Published by BMJ in Archives of Disease in Childhood
- Vol. 79 (6) , 478-480
- https://doi.org/10.1136/adc.79.6.478
Abstract
AIM To evaluate the risk factors for breakthrough varicella in a follow up study of a cohort of 181 healthy children immunised when aged 9–24 months with a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka). DESIGN The children were randomised in a double blind manner into one of four groups to receive one of two production lot vaccine batches, at two different titres (high titre, 103.9 and 104.0 plaque forming units (pfu); low titre (heat exposed), 102.7 and 102.8 pfu). The overall seroconversion rate after immunisation was 99%. RESULTS One hundred and sixty eight patients were available for review after a mean (SD) follow up of 35 (9) months after vaccination. Multivariate analysis indicated that risk factors for breakthrough varicella were household contact with varicella (adjusted odds ratio (OR), 19.89; 95% confidence interval (CI), 18.39 to 21.39), vaccination age of ⩽ 14 months (adjusted OR, 2.30; 95% CI, 1.69 to 2.90), and receiving low titre (102.7 pfu) vaccine (adjusted OR, 2.13; 95% CI, 1.54 to 2.73). All children who developed breakthrough varicella, had a modified varicella illness, except for three, all of whom had received low titre vaccine. CONCLUSION The identification of young immunisation age (⩽ 14 months) and low titre vaccine as risk factors for breakthrough varicella have important implications for the implementation of varicella vaccination programmes in healthy children.Keywords
This publication has 22 references indexed in Scilit:
- Varicella-Zoster Virus VaccineClinical Infectious Diseases, 1997
- Efficacy Of High-Titer Live Attenuated Varicella Vaccine In Healthy Young ChildrenThe Journal of Infectious Diseases, 1996
- Varicella Vaccine: The Japanese ExperienceThe Journal of Infectious Diseases, 1996
- Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy childrenEuropean Journal of Pediatrics, 1996
- Acyclovir and Prednisolone Treatment of Acute Infectious Mononucleosis: A Multicenter, Double-Blind, Placebo-Controlled StudyThe Journal of Infectious Diseases, 1996
- Varicella vaccineVaccine, 1995
- Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccineThe Journal of Pediatrics, 1995
- Varicella-Zoster Virus (VZV) Reactivation Is Related to the Low Response of VZV-Specific Immunity after Chickenpox in InfancyThe Journal of Infectious Diseases, 1994
- Modified cases of chickenpox after varicella vaccinationThe Pediatric Infectious Disease Journal, 1992
- Live Attenuated Varicella Virus VaccineNew England Journal of Medicine, 1984